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AI allelic imbalance 
AML acute myeloid leukemia 
AMLCG German AML Cooperative Group 
AMLSG German-Austrian AML Study Group 
AS alternative splicing 
cDNA complementary DNA 
CNV, -s copy number variation, -s 
DNA-seq DNA sequencing 
dNTP, -s deoxynucleoside triphosphate, -s 
EHA European Hematology Association 
ELN European Leukemia Net 
INDEL, -s insertion deletion, -s 
mRNA messenger RNA 
NGS next-generation sequencing 
pre-mRNA precursor messenger RNA 
RNA-seq RNA sequencing 
rRNA ribosomal RNA 
SBS sequencing by synthesis 
SF  splicing factor 
snRNP, -s small nuclear riboprotein, -s 
SNP, -s single nucleotide polymorphism 
SNV, -s single nucleotide variation, -s 
VAF, -s variant allele frequency, -ies 
VC variant calling 
WES whole exome sequencing 
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1. Acute myeloid leukaemia  
Acute myeloid leukaemia (AML) is a malignant neoplasm with an incidence of 4.3 per 
100.000 men and women every year, which corresponds to a lifetime risk of receiving 
an AML diagnosis of 0.5%.1 The scientific community has invested a sizeable amount 
of time, effort and resources into improving the prognosis of AML. However, despite 
continuous improvement, the relative five-year survival rate of AML is still only at 
28.7%.1 The advent of next-generation sequencing (NGS), has revolutionized the field 
of cancer genomics. NGS continues to provide scientists and medical professionals 
with new ways to improve the diagnosis and classification of neoplasms and builds the 
foundation for new treatment options through the identification of cancer-specific, 
molecular targets.2 In AML specifically, NGS methods have allowed scientist to detect 
recurring mutations with high accuracy, observe their pattern of co-expression and 
shed light on their often genome-wide consequences on core biological processes.3,4 
In this thesis two articles are presented, which employ two complementary NGS 
methods in conjunction with standard statistical tools in order to investigate the 
pathomechanisms of recurring mutations in AML.  
Acute myeloid leukaemia refers to a group of malignant neoplasms that are derived 
from undifferentiated myeloid precursor cells.5 The disease is characterized by rapid 
clonal expansion of myeloid blasts in the bone marrow and peripheral blood, leading 
to impaired haematopoiesis and bone marrow failure. Depending on the impaired cell 
line, patients may present with symptoms of anaemia (lethargy and fatigue, shortness 
of breath, pale skin), easy bruising or unusual bleeding (e.g. frequent nosebleeds, or 
bleeding from the gums), fever and frequent infections. Known risk factors include old 
age, male sex, exposure to radiation or carcinogenic chemicals (e.g. benzene), other 
blood disorders such as myelodysplastic syndrome, previous chemotherapeutic 
treatment and certain genetic disorders such as Down syndrome. Although several 
treatment options are available, including allogeneic stem cell transplants, the disease 
is often refractory or recurs after treatment.6 
Carcinogenesis and consequently leukaemogenesis has been linked to mutations that 
disrupt the balance between proliferation and programmed cell death (apoptosis) 
leading to uncontrolled cell growth. The emergence of new technologies, especially 
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next-generation sequencing, has led to the discovery of genes that are recurrently 
mutated in AML and other haematopoietic malignancies.7–9 This has shifted the focus 
from morphological classifications of AML to more accurate cytogenetic and molecular 
classifications that have improved the diagnosis and management of the disease. One 
such classification, the European Leukemia Net (ELN) 2017 classification includes a 
large spectrum of cytogenetic and molecular parameters and has supported physicians 
in the selection of treatment options for AML patients.10 The parameters of the ELN 
2017 classification were used in Publication I in order to create a regression model with 
the purpose of characterizing the prognostic relevance of splicing factor (SF) 
mutations, which make up a relevant portion of the recurring mutations in AML.4 A 
prerequisite for interpreting the impact of SF mutations is understanding the process 
of splicing, a core concept of cancer genomics and molecular biology in total for that 
matter.11 The next section covers this biological mechanism and its implications for the 





The central dogma of molecular biology states that the information in a cell flows via 
transcription from DNA to RNA, which is then translated into a polypeptide sequence 
(a protein) that executes a specific function in the cell.12 In the past decades scientist 
have taken a closer look at this process and have refined our understanding of it. The 
regions on the DNA that are transcribed to RNA are referred to as genes. While all 
genes are by definition transcribed to RNA, only messenger RNA (mRNA) is used as 
a template for the synthesis of a protein. However, the initial product of transcription is 
in the vast majority of cases a precursor messenger RNA (pre-mRNA). This primary 
transcript must undergo processing prior to translation. Several post-transcriptional 
modifications take place, such as 5’-capping, polyadenylation (which is used for 
poly(A) selection of mRNA in RNA-seq experiments13) and splicing.  
 
2.2. The splicing process 
The term splicing refers to the removal (cleavage) of non-coding regions of the pre-
mRNA and the ligation of the remaining fragments. Regions on the pre-mRNA that 
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contain information for protein coding are termed exons, while non-coding regions are 
referred to as introns. The molecular machine responsible for splicing is the 
spliceosome, which is comprised of five small nuclear RNAs and a number of 
associated protein factors that combine and form small nuclear riboproteins (snRNPs). 
In eukaryotic organisms, the major spliceosome that is responsible for splicing most 
genes is comprised of five such snRNP units (U1, U2, U4, U5 and U6) that assemble 
anew on each pre-mRNA.14,15  
 
 
Figure 1: mRNA splicing. Schematic illustration depicting the core steps of the splicing process. 
Illustration taken from Wikimedia Commons where it is available under a Creative Commons license 
(https://en.wikipedia.org/wiki/RNA_splicing#/media/File:RNA_splicing_reaction.svg).  
 
Splicing occurs at specific conserved sequences that are found at the 5’ and 3’ ends 
of the spliced intronic sequence and are known as splice sites. Another critical 
sequence for splicing is the branch point, which is a sequence usually located a few 
bases (~20-50) upstream of the 3’ splice site that is loosely conserved, but always 
contains an adenine nucleotide.16 The process is initiated by the binding of the U1 
snRNP unit to the 5’ splice site, committing the pre-mRNA to splicing. This causes the 
5’ splice site to pair with the adenine at the branch point through a chemical process 
called transesterification. This requires the pre-mRNA to “bend” and form a circular 
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structure called a “lariat”. The free 3’-end of the upstream exon is covalently bound to 
the 5’ splice site and the lariat structure is cleaved away, concluding the splicing 
process (Figure 1).14  
 
2.3. Alternative splicing 
In the past decades, scientist have observed that a gene can produce multiple products 
although it is a singular template. This capability of genes is facilitated by a process 
referred to as alternative splicing (AS), which is a major contributor of proteomic 
diversity between individuals and different tissue types in an individual.17 While up to 
the beginning of the 21st century this process was believed to be an exception, current 
studies suggest that it is in fact a universal phenomenon that occurs in up to 95% of 
human genes.18,19 Alternatively spliced genes can produce several transcripts 
isoforms, which are translated 
into proteins that can serve different or even opposing purposes.17,20 AS has also been 
linked to other cellular mechanisms, including gene regulation21,22 and intracellular 
transport of mRNAs and proteins.23,24 AS can produce transcript isoforms, where an 
exonic sequence is excluded or an intronic sequence is included. Four main types of 
AS have been described: a “cassette” exon, mutually exclusive exons, alternative 5’ or 
3’ splice sites and intron retention and are shown in Figure 2. A cassette exon 
describes an exon that is included in one isoform, but excluded completely from 
another. Mutually exclusive exons are not spliced in together in one isoform, i.e. when 
one exon is spliced in, the other exon is spliced out. Alternative splice sites refer to the 
fact that splicing can occur upstream or downstream of the 5’ or 3’ splice sites at a 
sequence, which also contains a splice junction motif. Finally, intron retention refers to 
the inclusion of an intronic sequence in the final mature mRNA product. 
 
2.4. Identification of disease-relevant aberrant splicing 
Splicing and AS, are highly regulated processes.25 However, mutations can induce 
aberrant splicing in cancer cells.26 The resulting aberrant transcript isoforms are 
translated into proteins that are missing domains or are truncated. As a consequence, 
proteins may be degraded prematurely (e.g. through nonsense-mediated decay27), 
have severe functional impairments, or may even present with a completely new 
function. 
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Figure 2: Modes of alternative splicing. The 
most common types of alternative splicing are 
shown. Exons are colored blue and introns are 
depicted in yellow. The blue lines connecting 
exons represent splice junctions. Illustration 
taken from Wikimedia Commons where it is 
available under a Creative Commons license. 
(https://commons.wikimedia.org/wiki/File:Alt
_splicing_bestiary2.jpg)    
 
Increasing evidence has come to light that 
aberrant splicing is integral to cancer 
development and thus a growing body of 
research aims at uncovering aberrant 
splicing patterns in tumor cells. The recent 
discovery of mutations in genes, which are 
directly involved in the transcription and 
splicing pathway (e.g. SF mutations), has 
provided an additional incentive.28 The 
emergence of RNA-seq has greatly contributed to the detection of aberrant splicing, 
as it comes with genome-wide capabilities of splice junction detection. Through 
transcriptome assembly tools it is possible to reconstruct transcript isoforms of a 
sample or a sample group and compare them to an existing reference transcriptome, 
thereby detecting novel transcript isoforms.29 The usage of tools with powerful novel 
splice junction detection algorithms has also supported the identification of aberrant 
splicing. The following sections cover the fundamentals of NGS and its applications in 
molecular biology using the Illumina sequencing method as an example. 
 
3. Next-generation sequencing 
 
3.1. Overview 
Sequencing in molecular biology refers to the identification of the primary order of 
biological structures. Depending on the genomic region studied, DNA-sequencing 
(DNA-seq) can be classified into whole genome sequencing (WGS; sequencing of the 
11
complete DNA of an organism), whole exome sequencing (WES; only gene-coding 
regions are sequenced) or targeted sequencing (only selected genomic regions are 
sequenced). RNA-sequencing (RNA-seq) provides the ability to sequence the total 
transcriptome of a sample (whole transcriptome sequencing; corresponds to WES). 
However, RNA-seq can also be used to study specific RNA populations, such as 
mRNA, micro RNA, transfer RNA and ribosomal RNA (rRNA) or more recently the total 
RNA population of a single cell (single-cell RNA sequencing30). Other applications 
include ribosomal profiling and targeted RNA-seq.31  
The sequencing data analyzed in this thesis included both DNA and RNA data and 
was created on an Illumina sequencing platform, the most broadly used, commercially 
available NGS platform.32 A typical Illumina NGS workflow consist of four steps: library 
preparation, cluster (“bridge”) amplification, sequencing by synthesis, and data 
analysis. The studies presented in this thesis cover different ways of interpreting NGS 
data and thus fall under the data analysis step. However, accurate data analysis 
requires understanding of all steps of an NGS workflow, which is why they will briefly 
be covered in the following sections.  
 
3.2. Library preparation  
Prior to the actual sequencing process a sequencing library (a collection of DNA or 
complementary DNA (cDNA) fragments) needs to be created, which will serve as the 
primary sequencing input. This creation process is called library preparation and 
requires isolated and purified DNA or RNA.33 Core steps in the isolation and purification 
of DNA include cell lysis, the removal of membrane lipids, the denaturation and 
removal of proteins (through protease treatment), and other cellular components, as 
well as the removal of RNA through ribonuclease treatment. Common DNA extraction 
and purification methods are organic extraction, magnetic separation, silica-based and 
anion exchange technology.34,35 The use of a specific extraction kit varies depending 
on the sample source type. While the process of RNA isolation and purification is 
similar to DNA purification, the ubiquitous presence of RNases in the environment 
(including human skin) provide an additional challenge in the collection of intact RNA 
molecules. The most common RNA extraction methods are the acid guanidinium 
thiocyanate-phenol-chloroform extraction and silica-based methods.36 In most RNA-
seq studies only the mRNA is of interest, however rRNA accounts for most (~80%) of 
the RNA in eukaryotic organisms. Therefore, an additional step to enrich for mRNA is 
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required. Two common methods that address this issue are poly(A) selection and rRNA 
depletion, each having their own advantages and drawbacks.13,37–41 In the whole-
transcriptome RNA-seq protocol used to generate data for the studies presented in this 
thesis poly(A) selection was used to enrich for mRNA. The RNA molecules of interest 
are then converted into cDNA molecules through reverse transcription.  
The obtained DNA (or cDNA) molecules are fragmented into smaller segments (usually 
a few hundred base pairs each), through mechanical methods (e.g. sonication, 
nebulization) or enzymatic methods (e.g. enzymatic digestion42,43), which is followed 
by the 3’ and 5’ ligation of synthetic oligonucleotides (known as adapters) to the 
fragments. The final library preparation step includes polymerase chain reaction 
amplification and gel purification of the adapter-ligated fragments. The inclusion of 
unique, library-specific index sequences in the adapters, called multiplexing, permits 
the pooling and concurrent sequencing of up to 96 samples in a single sequencing run 
and has contributed significantly to the increased output potential of NGS methods.  
 
3.3. Cluster generation 
The cluster generation step begins by loading the adapter-ligated fragments onto a 
proprietary flow cell. The flow cell is, in essence, a glass slide with up to eight physically 
separate lanes, each of which can host an independent analysis. The flow cell is coated 
with oligonucleotide sequences that are complementary to one of the adapter 
sequences of the fragments, which allows for the binding of the fragments to the flow 
cell. A polymerase then creates a complement to the bound fragment. The double-
stranded DNA is then denatured and the original fragment (forward strand) is washed 
away, leaving only the reverse complement (reverse strand), which is covalently bound 
to the flow cell.  
Clusters are created through a procedure known as bridge amplification. During this 
procedure, the free end of the bound reverse strands bends over and binds (“bridges”) 
to the oligonucleotide bound on the flow cell, which is complementary to its free end. 
The strands are then amplified through repeated extension and denaturation cycles. 
As the fragments are continuously bound on one end to the flow cell, the clonal 
amplification takes place locally, resulting in millions of unique clonal clusters across 
the flow cell. These clusters contain both the forward and the reverse strand of each 
original molecule. The reverse strand is cleaved and washed away prior to the actual 
sequencing process.  
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In the case of paired-end sequencing, where sequences are created in pairs, the 
reverse strand is synthesized again after the sequencing of the forward strand has 
been concluded and the forward strand is cleaved and washed away. The reverse 
strand is then sequenced as well, resulting in a sequencing pair (a “paired-end” read). 
Paired-end sequencing is currently used for most scientific questions, including the 
ones addressed in the studies presented in this thesis, as it is more time efficient and 
more accurate in the detection of artifacts, genomic rearrangements and insertion-
deletion variants, as opposed to single-end sequencing.44 Nevertheless, single-end 
still finds its applications (e.g. in small RNA sequencing).  
 
3.4. Illumina sequencing by synthesis (SBS) 
The standard Illumina sequencing by synthesis (SBS) method uses fluorescently-
labeled deoxynucleoside triphosphates (dNTPs), which contain an element that can 
reversibly terminate polymerization. These dNTPs each contain one of the four 
nitrogenous bases necessary to synthesize a DNA molecule (adenine, thymine, 
cytosine or guanine). Firstly, primers and polymerization enzymes are added to the 
flow cell. During each sequencing cycle, all four fluorescently-labeled dNTPs are 
added to the flow cell containing the clonally amplified forward strands. After the 
incorporation of a single dNTP, which happens in a massively-parallel fashion for all 
the clones across the flow cell, the polymerization is terminated and the remaining 
dNTPs are washed away. The concurrent presence of all four dNTPs leads to natural 
competition, thus reducing incorporation bias.45 After laser excitation, the fluorophores 
on the dNTPs incorporated in each cluster emit light at a characteristic wavelength, 
which is captured by a camera and used to identify the dNTP type, i.e. the nitrogenous 
base contained within the dNTP molecule. This method is not sensitive enough to 
capture the light emitted from a single molecule, however the clonal amplification step 
prior to sequencing allows for accurate identification of the incorporated dNTP by signal 
enhancement. The certainty with which a base is identified depends on the signal 
intensity captured and is quantified through a Phred quality score (Q score).46 After the 
base has been identified the reversible polymerization terminator is enzymatically 
cleaved along with the fluorophore, ending the sequencing cycle. The repetition of 
multiple sequencing cycles results in a sequence of bases (a “read”), which in Illumina 
sequencing usually has a length between 50 and 300 base pairs (bp). If paired-end 
sequencing is performed, the reverse strand is also sequenced and the end result are 
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two sequences of equal length with an unsequenced region of a few hundred bp in 
between. Millions of these pairs are created per sample and used for the subsequent 
data analysis.  
  
3.5. Data analysis 
The data analysis for DNA and RNA sequencing is computationally intensive and thus 
requires time- and memory-efficient tools. As the cost for sequencing decreases at a 
fast pace and therefore sequencing experiments tend to have larger sample sizes, the 
need for specialized tools that scale well with increasing input size and have multi-
threading capabilities intensifies. Each analysis pipeline must be customized to answer 
the biological question at hand, however some core steps exist that are mandatory in 
most analyses.  
Prior to any analysis, samples need to be demultiplexed, if multiplexing has occurred 
during library preparation, as each sample usually represents a biological or technical 
replicate. This process should be followed by a quality control step, where each sample 
is checked for sufficient coverage over the genomic regions covered in the experiment, 
as well as the average read quality elicited from the Phred score provided by the 
sequencer.46 Depending on the quality of the reads some reads or rarely whole 
samples may need to be excluded from downstream analysis, however in most cases 
trimming of the reads (removal of low quality 3’ or 5’ bases) is sufficient. Tools that 
possess trimming capabilities can frequently also remove (incomplete) adapter 
sequences that were not removed sufficiently by the sequencer.  
The quality-controlled reads are then (in most experiments) “aligned” to the reference 
genome, meaning that a computational tool identifies the genomic location from which 
these reads originated and maps them to specific genomic coordinates. This task 
differs between DNA- and RNA-seq, as for RNA-seq reads splicing has occurred, 
therefore aligners need to be “splice-aware”. This procedure is followed by another 
quality control step to assess the quality of the alignment.  
Sequencing workflows usually diverge after alignment and are tailor-made to fit the 
scientific research question examined. Some common applications of a sequencing 
data analysis are variant calling, gene and isoform expression analyses, gene fusion 
detection and the detection of novel isoforms. For some analyses DNA-seq data 
provide more accurate results (e.g. variant calling, an issue addressed in Publication 
II), while others are only possible with RNA-seq data (e.g. novel isoform detection). A 
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variant calling pipeline was the cornerstone of Publication II. The core concepts of 
variant calling, as well as its capabilities and limitations are covered in the following 
sections.   
 
4. Genomic variants 
 
4.1. Classification 
Genomic variants are present ubiquitously across the genome and contribute to the 
genomic diversity of a species. The term variant is neutral in respect to the effect of 
the genomic variation, while the term polymorphism usually describes a benign 
variation. However, there is no clear distinction and the term single nucleotide 
polymorphism (SNP) is often used synonymously with the term single nucleotide 
variation (SNV). In contrast, the term mutation is usually reserved for a variant with a 
harmful effect often in association with a specific disease.  
When variants are mentioned in the context of sequencing experiments they refer to 
genomic variations that exist in the sample or samples studied compared to the 
reference genome (sequencing variant). They can be classified according to their type 
into single nucleotide variations, insertions, deletions and substitutions, as well as 
structural variants and chromosomal aberrations. SNVs are sequence variations where 
the sample examined has a single different nucleotide compared to the reference 
genome. Insertions describe the addition of a nucleotide sequence to the genome, 
while deletions describe the removal of a nucleotide sequence. Substitutions occur 
when a sequence of nucleotides is replaced by another nucleotide sequence and is 
usually reserved for cases where both the replacing and the replaced sequences have 
the same length. In contrast INDELs, short for insertion and deletion polymorphisms, 
describe the insertion or deletion of a sequence, resulting in an absolute difference in 
the number of nucleotides. The term is also used for cases where both an insertion 
and a deletion occur at the same genomic coordinates or it is not possible to clearly 
distinguish between them. Structural variants affect a large genomic region (usually > 
1000bp) and can present themselves as deletions, duplications, insertions, inversions, 
translocations and copy number variations (CNVs). CNVs are repetitions of a specific 
genomic segment a set number of times that can differ between individuals. Similarly, 
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chromosomal abnormalities affect a large genomic sequence (the term is loosely 
defined) with often severe functional impairments (e.g. Trisomy 21).  
INDELs can be further classified into frameshift and non-frameshift INDELs. A 
frameshift is defined as the occurrence of an INDEL in a coding region of the genome, 
which causes a nucleotide difference that is not a multiple of three. As a triplet of 
nucleotides (a codon) is translated into an amino acid, a shift in the reading frame of a 
coding region leads to a completely altered sequence of amino acids in the resulting 
protein. As the stop codon (the last codon signifying the end of the translation process) 
is also altered, the protein can be truncated or abnormally long and is very like to have 
an impaired or completely lacking function. The earlier in the reading frame a frameshift 
occurs, the more detrimental the effect on the protein function will be. Non-frameshift 
or in-frame INDELs cause an insertion or deletion (or both) that is divisible by three.  
Lastly, mutations can be classified according to their effect on the amino acid sequence 
of a protein (Figure 3). Mutations that do not alter the amino acid sequence are called 
“silent” mutations and are usually benign. Conversely, mutations that lead to a different 
amino acid sequence are termed “missense” mutations. Frameshift mutations or 
substitutions that introduce a stop codon usually lead to a completely altered or 
truncated amino acid sequence and are called “nonsense” mutations, as the protein 
can no longer fulfill its function.  
 
 
Figure 3. Effect of point mutations on protein structure. Mutations can be characterized according 
to their effect on the amino acid sequence of the resulting protein into silent, nonsense or missense 
mutations. Missense mutations can be further classified based on the similarity (in terms of chemical 
properties) between the resulting amino acid and the amino acid that would have resulted from the 
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unmutated RNA sequence. Illustration taken from Wikimedia Commons where it is available under a 
Creative Commons license (https://en.wikipedia.org/wiki/File:Different_Types_of_Mutations.png).    
 
4.2. Variant calling 
Variant calling (VC) describes the in silico process by which sequencing variants are 
identified from sequencing data. After a sample has been sequenced and aligned to 
its corresponding reference genome, the alignment file undergoes quality control and 
pipeline specific filtering steps. The alignment file then serves as input for VC tools. 
The underlying algorithm of VC tools checks for sequence variations between aligned 
reads and the reference genome. If a variant is present in a sufficient number of reads 
(criteria are provided by the user), the detected variant is “called” and its genomic 
coordinates are provided along with the type of variation (e.g. SNV or INDEL). One 
additional critical information that is provided by VC tools, is the variant allele frequency 
(VAF). The VAF is a measure of frequency, which represents the relative frequency of 
a variant in a specific gene locus. The gene locus containing a variant is called an allele 
(therefore variant allele frequency).  
In a sequencing experiment, if a variant is detected in 20 out of 100 reads, it has a VAF 
of 20%. As the VAF depends on the number of reads covering a genomic region, the 
more coverage a region has (the higher the sequencing depth) the more accurate the 
VAF will be. Additionally with increasing coverage, variants with low VAF can be 
detected. The VAF is often used to determine whether a variant is valid or the result of 
a sequencing error. Due to the direct dependence of the VAF on the coverage of the 
genomic locus, targeted sequencing experiments, where a few loci are sequenced with 
a high sequencing depth, are superior to whole genome/transcriptome sequencing, 
where the coverage over individual genomic regions tends to be low. Furthermore, as 
mRNA undergoes post-translational modifications and RNA-seq is more prone to 
sequencing errors, DNA-seq is the preferred sequencing method for VC.47  
When both the variants and the RNA expression profile of an individual is of interest, 
as is often the case in cancer samples, a joint approach using both DNA- and RNA-
seq is used. A limited amount of studies have compared VC in samples where both 
DNA and RNA sequencing data is available and observed that the VAFs of variants 
can differ significantly between DNA- and RNA-seq.47 When such a difference is 
observed it is coined allelic imbalance (AI).48 For example, in a sample where a variant 
has a VAF of 10% in DNA-Seq and a VAF of 50% in RNA-seq, AI is present. One of 
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the underlying biological mechanisms that leads to an AI is termed allele-specific 
transcription. Allele-specific transcription describes the fact that one allele is 
transcribed disproportionally with respect to its VAF, a phenomenon especially 
interesting when it occurs in mutated cancer-related genes.48 The next section covers 
allelic imbalance along with alternative splicing as pathomechanisms of recurring 
mutations in AML patients.  
 
5. Differential splicing and allelic imbalance as pathomechanisms of recurring 
mutations in AML 
In the studies presented in this thesis the authors attempted to illuminate the 
pathomechanism of recurring mutations in AML. Both studies included an in silico 
analysis using whole-transcriptome RNA-sequencing and shared several common 
data analysis steps. All patients who received RNA-sequencing were participants in 
two trials of the German AML Cooperative Group (AMLCG). The trials were 
randomized phase III trials and patients were treated with intensive induction 
chemotherapy. Matched targeted DNA-seq and cytogenetic data was available for all 
RNA-seq patients. Additional cohorts were used for validation and are highlighted 
below. The first study focused on SF genes harboring recurring mutations in AML, 
while the second study analyzed 11 recurrently mutated genes with respect to the 
presence of AI.  
 
Publication I:  
In this study we examined mutations in the three most commonly affected SF genes in 
AML, namely the Serine/arginine-Rich Splicing Factor 2 (SRSF2), the U2 small nuclear 
RNA Auxiliary Factor 1 (U2AF1) and the Splicing Factor 3B Subunit 1 (SF3B1). 
Mutations in these genes are, in the majority of cases, heterozygous point mutations 
and rarely co-occur within the same patient.49,50 They have been shown to occur early 
on in cancer evolution and are common events in MDS and AML that frequently 
coincide with other recurring mutations.8,51 Several studies have characterized them 
thoroughly in MDS and have highlighted their importance as independent prognostic 
markers.3,52,53 Furthermore, two large RNA-seq studies have been performed on MDS 
patients delineating the splicing changes that they induce, leading to the dysregulation 
of several disease-relevant genes.52,54 Corresponding previous literature in AML 
patients is limited to small sample sizes and specific AML subgroups.55  
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In the first part of the study the clinical characteristics of SF mutated patients are 
outlined in two large cohorts (AMLCG cohort, n = 1119 and AMLSG cohort, n = 1540, 
Figure 4) treated in randomized clinical trials. The large number of SF mutated patients 
(n = 216; AMLCG cohort) enabled the analysis of the four most frequent individual 
point mutations: SRSF2(P95H), SRSF2(P95L), U2AF1(S34F) and SF3B1(K700E). SF 
mutations were correlated with demographic and molecular parameters using standard 
statistical tests. Briefly, our findings show that SF mutations are frequent in AML and 
even more frequent in elderly and secondary AML patients and are co-expressed with 
a number of recurrent mutations. A survival analysis using Kaplan-Meier curves and 
log-rank testing showed that SF mutated patients presented with inferior relapse-free 
survival and overall survival (Figure 4), which could be validated with simple Cox 
regression models. However, multiple Cox regression models incorporating 
parameters of the ELN 2017 classification did not show that SF mutations are individual 
prognostic markers.  
 
 
Figure 4: Overall survival of SF 
mutated patients (Bamopoulos et al. 
2020, Supplementary Material56). 
Kaplan-Meier graphs for patients with 
SRSF2 (A), U2AF1 (B), and SF3B1 (C) 
mutations and SF wildtype patients 
showing overall survival (censored for 
transplant). P-values correspond to log-
rank tests. Tables at the bottom of the 
graphs correspond to numbers at risk 




For the functional analysis of SF mutations an RNA-seq analysis was performed on a 
subgroup of the AMLCG cohort (n = 246). In addition, a subset of the Beat AML cohort 
(n = 177)9 was used for validation. In a first step, a differential isoform expression 
analysis showed little overlap in the genes differentially expressed in each SF mutant 
subgroup. This was confirmed through unsupervised clustering, which showed an 
expression profile characteristic for each SF mutation, with several dysregulated genes 
being cancer-relevant genes. We next developed a novel differential splice junction 
usage pipeline to identify splice junctions that are over- or underused in SF mutants. 
Importantly, this pipeline allows for the accurate detection of both known and novel 
splice junctions, which we were able to show by validating our findings in the Beat AML 
cohort. A gene ontology analysis combing the differential isoform expression and 
differential splice junction usage analysis results supported a strong dysregulation of 
the splicing pathway in SF mutants. Lastly, we identified two splice junctions in the 
genes EVL and NBEAL2 the usage of which correlated with worse prognosis in both 
datasets analyzed, thereby exemplifying the clinical relevance of our approach (Figure 
5).  
In summary, this study provides a comprehensive overview of SRSF2, U2AF1 and 
SF3B1 mutations in AML patients. The first half covers their frequency and association 
with patient characteristics and other molecular markers in AML, while also showing 
that they do not have independent prognostic value for patient survival in AML. The 
latter half consist of a functional RNA-seq analysis highlighting differentially expressed 
isoforms in AML-related genes, while also shedding light on the genome-wide effect of 




Figure 5. Differential splice junction usage correlates with patient survival (Bamopoulos et al. 
202056). Cox regression models incorporating normalized measurements of splice junction usage for 
one junction in the gene EVL and one in NBEAL2 showed that the usage of these splice junctions can 
predict patient overall survival (also visualized with Kaplan-Meier graphs). The junction in EVL showed 
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Publication II:  
Mutations and their contribution to cancer are a central focus of current cancer 
research. However, few studies have focused on whether recurrent mutations are 
transcribed from DNA to RNA and whether the observed transcripts are proportional 
to the DNA VAF of those mutations.48,57,58 One reason for this omission is the difficulty 
of identifying true genomic variants in RNA-seq data, mostly due to the large number 
of false positive variants, which is why DNA-seq is still considered the gold standard 
for variant discovery.59 In this study, we established a pipeline that enables the 
comparison of DNA-seq and RNA-seq variant calling results to determine allelic 
imbalance using mutations in recurrently mutated AML genes.  
For our analysis we considered 36 genes recurrently mutated in our dataset with a VAF 
of >1%. Out of those, 11 met our filtering criteria and were considered for further 
analysis. Variants were categorized to DNA-exclusive, RNA-exclusive or transcribed 
variants (when detected in both DNA- and RNA-seq). As expected due to sequencing 
errors, RNA-exclusive variants were relatively high (47.9% of all variants), which 
necessitated strict filtering criteria to remove false positives. For this purpose we 
calculated the proportion of heterozygous to homozygous mutations, which stabilized 
at a cut-off of around 10x. Additional filtering criteria further reduced false positives. 
After application of the filtering criteria, most variants detected in DNA-seq could also 
be detected in RNA-seq (95.4%). Of these around 5.3% were overrepresented in RNA-
seq, while 9.9% could not be detected in RNA-seq.  
The large differences in coverage between targeted DNA-seq and whole-transcriptome 
RNA-seq, which are common in these approaches require a workflow that addresses 
this issue. We solved this by defining a “weighted” AI based on the differences between 
expected and observed mutant allele reads. Using weighted AI in a regression model 
we showed imbalance towards wild-type transcript abundance in CEBPA, PTPN11 and 
WT1. In contrast, in GATA2, IDH2, NPM1, RUNX1, SRSF2 and TET2 an AI towards 
the mutant allele was observed (Figure 6). An analysis of SNPs in these genes did not 
identify any AI, suggesting that AI is specific to recurrent mutations in these genes. 
Using pooled sample data from three additional cohorts (DKTK, TCGA and HELSINKI 
cohorts) we were able to validate an AI towards the mutant-allele for GATA2. 
Differential isoform expression analysis was performed to check whether preferential 
expression of the mutant alleles correlated with the differential expression of specific 
isoforms, which however was not the case.  
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Figure 6. Weighted allelic imbalance of recurring AML mutations (adapted from Batcha et al. 
201960). Weighted allelic imbalance is shown separately for SNVs and INDELs. A value below one 
signifies an allelic imbalance towards the wildtype allele. Conversely, a value above one denotes an 
allelic imbalance towards the mutant allele. 
 
In summary, we established a method to compare the VAFs of variants in DNA and 
RNA and defined several filtering criteria to remove false positive variants while 
retaining as many likely true variants as possible. Using this method we were able to 
show AI for 9/11 recurrently mutated genes examined in this study, which correlated 
with the presence of recurrent mutations, but not with common SNPs present in these 
recurrently mutated genes. Our analysis suggests that AI is a common phenomenon 
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Acute myeloid leukemia is an aggressive malignancy which proves fatal if left 
untreated. Most patients respond to intensive chemotherapy, however refractory or 
relapsing disease is still a major contributor of poor patient outcome. New 
generation sequencing methods enabled the identification of genes harboring 
recurrent mutations in this disease, and they are being used to inform clinical 
decisions. In the studies presented in this thesis the aim was to improve our 
understanding of these mutations to further refine clinical decision making. The first 
study provided an overview of splicing factor mutations, which affect around 20% 
of all acute myeloid leukemia patients. It highlighted the association of splicing 
factor mutations with clinical and molecular parameters and further showed that 
splicing factor mutations are not independent prognostic markers in acute myeloid 
leukemia. A novel differential splice junction usage pipeline was used to quantify 
aberrant splicing patterns in mutated patients in two large sequencing datasets. 
The usage of two splice junctions was shown to identify patients with poor 
prognosis thereby providing an example of how our findings can be translated to 
clinical practice. The purpose of the second study was to examine allelic imbalance 
of recurrent mutations, a currently underappreciated phenomenon in acute myeloid 
leukemia. Using a large patient sample pool with matched DNA- and RNA-
sequencing data we were able to compare variant calling pipelines between both 
sequencing methods to determine whether recurrent mutations are over- or 
underrepresented in RNA. We defined weighted allelic imbalance as a parameter 
for statistically comparing variant allele frequencies between DNA and RNA and 
identified allelic imbalance in nine out of eleven recurrently mutated genes 
examined in this study. Furthermore, recurrent mutations in GATA2 were also 
shown to exhibit preferential transcription for the mutant allele in a pooled validation 
cohort of three independent datasets. In summary, our studies show how 
customized bioinformatics pipelines can lead to an improved pathomechanistic 
understanding of recurrent mutations in acute myeloid leukemia and provide a 




GERMAN SUMMARY / DEUTSCHE ZUSAMMENFASSUNG 
 
Die Akute Myeloische Leukämie ist eine aggressive Krebserkrankung die 
unbehandelt tödlich verläuft. Die Mehrheit der Patienten spricht auf eine intensive 
Chemotherapie an, jedoch resultieren refraktäre Erkrankungsverläufe oder 
Rezidive immer noch in einer schlechten Gesamtprognose. Hochdurchsatz-
Sequenzierungsverfahren erlaubten die Identifikation von Genen, die in dieser 
Erkrankung häufig mutiert sind. Diese Mutationen ermöglichen eine 
Risikostratifizierung der Patienten und fließen in Therapie-Entscheidungen ein. Das 
Ziel der in dieser Dissertation präsentierten Studien war es, die funktionelle 
Bedeutung einiger dieser Mutationen genauer zu charakterisieren. Die erste Studie 
charakterisierte Spliceosom-Mutationen, die bei etwa 20% aller Patienten mit einer 
Akuten Myeloischen Leukämie beobachtet werden. Die Assoziation von 
Spliceosom-Mutationen mit klinischen und molekularen Parametern wurde 
untersucht und zeigte, dass Spliceosom-Mutationen keine unabhängige 
prognostische Wertigkeit besitzen. Eine neue Analyse-Methode zur Splicing-
Quantifizierung wurde zur Untersuchung von aberranten Splicing-Mustern in 
Patienten mit Mutationen in diesen Genen entwickelt. Diese wurde in der Folge auf 
zwei große Sequenzierdatensätze angewandt. Zwei der aberranten Splicing-
Muster konnten genutzt werden, um Patienten mit einer schlechten Prognose zu 
identifizieren und stellen damit die klinische Bedeutung der Ergebnisse beispielhaft 
dar. 
Das Ziel der zweiten Studie war es, ein allelisches Ungleichgewicht von häufigen 
Mutationen zu untersuchen. Mittels eines großen Patientenkollektivs mit gepaarten 
DNA- und RNA-Sequenzierungsdaten konnten eine Über- oder 
Unterrepräsentation von häufigen bei AML Patienten beobachteten Mutationen auf 
RNA-Ebene bestimmt werden. Wir definierten die “weighted allelic imbalance” als 
einen Parameter für den statistischen Vergleich der Allelfrequenzen von 
rekurrenten Mutationen in DNA und RNA und stellten ein allelisches 
Ungleichgewicht in neun von elf untersuchten Gen-Mutationen fest. Weiterhin 
konnte die bevorzugte Transkription des mutierten Allels von GATA2 in einer 
Validierungskohorte, bestehend aus drei unabhängigen Datensätzen, gezeigt 
werden.  
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Zusammenfassend, zeigen diese Studien wie maßgeschneiderte bioinformatische 
Arbeitsabläufe zu einem verbesserten pathomechanistischen Verständnis von 
rekurrenten Mutationen in der Akuten Myeloischen Leukämie führen können und 
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